Close Menu

NEW YORK (GenomeWeb) – A team led by investigators at Brigham and Women's Hospital, Harvard Medical School, and the Broad Institute has uncovered evidence that checkpoint blockade immunotherapy response may involve shifts in the activity of tumor microenvironment T cells that do not express receptors for the immune checkpoint proteins that such therapies target.

"Our study broadens the focus of what checkpoint blockade therapy may be doing and how it mediates its effects," co-corresponding and co-senior author Ana Anderson, a BWH researcher, said in a statement.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.